A new analysis finds that only a small fraction of annotated long non-coding RNAs have measured half-lives, leaving the proposed stability-based discovery bias largely untestable.
Moderna’s drugs share the same building blocks and the same factories. Only the code changes. We knew from the beginning that it was going to be zero drugs or a lot of drugs. It made no scientific ...
Until now, the flu shot lineup featured six vaccination options —using live viruses, inactivated viruses or viral antigens—delivered via needle injection or nasal spray. The mRNA vaccine has proven ...
Discover expert insights into single-cell proteomics, revealing protein diversity and non-canonical biology with advanced ...
CRISPR pioneer Jennifer Doudna on the evolution of gene-editing technology, her own path, and what it takes to be a good scientist.
A research team led by distinguished professor Giuseppe Pezzotti at the Biomedical Engineering Center, Kansai Medical ...
Proprietary BRiSC™ platform to advance the discovery and development of next-generation dual-targeting siRNA medicines.
New research from ProQR Therapeutics and TNO explores an RNA-based approach to reducing cardiovascular disease risk without ...
The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera ...
A global survey of 102 cities uncovered nearly 55,000 RNA viruses, most previously unknown to science, revealing a hidden world of viral diversity.
A long non-coding RNA called RBMS3-AS3 has emerged as a powerful molecular accomplice in ovarian cancer, according to a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results